2022
DOI: 10.3390/ijms232012309
|View full text |Cite
|
Sign up to set email alerts
|

Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients

Abstract: Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 41 publications
0
2
0
Order By: Relevance
“…High serum ADMA levels may represent a risk factor for disease activity and poor prognosis among SLE patients. 135,136 Other potentially useful biomarkers are presented in Table 1. 121,131,[137][138][139] Biomarkers may help to detect SLE patients at high cardiovascular risk and need further investigation to develop personalized treatment.…”
Section: Advances In Diagnosticsmentioning
confidence: 99%
“…High serum ADMA levels may represent a risk factor for disease activity and poor prognosis among SLE patients. 135,136 Other potentially useful biomarkers are presented in Table 1. 121,131,[137][138][139] Biomarkers may help to detect SLE patients at high cardiovascular risk and need further investigation to develop personalized treatment.…”
Section: Advances In Diagnosticsmentioning
confidence: 99%
“…The antiphospholipid syndrome (APS) is a systemic autoimmune disorder whose diagnostic criteria were revised in 2006 at the Sydney workshop in Australia. Concisely, APS is characterized by persistent positivity for antiphospholipid antibodies [aPL, including lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2-glycoprotein1 antibodies (anti-β 2GPI)], thrombotic events and/or severe pregnancy morbidity [ 1 , 2 , 3 , 4 ]. Beyond the APS-related thrombotic and pregnancy complications, additional clinical conditions, such as cutaneous (livedo reticularis, cutaneous ulcers) haematological (thrombocytopenia, hemolytic anemia), cardiac (cardiac valvular disease), nephrological and neurological manifestations are associated to APS [ 5 ].…”
Section: Introductionmentioning
confidence: 99%